Cancer Research and Treatment

Original Articles

Rare cancer

Clinical Features of Li-Fraumeni Syndrome in Korea: Ran Song, Sun-Young Kong, Wonyoung Choi, Eun-Gyeong Lee, Jaeyeon Woo, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, So-Youn Jung; Cancer Res Treat. 2024;56(1):334-341. Published online August 9, 2023; DOI: https://doi.org/10.4143/crt.2023.794

Abstract PDF Supplementary Material PubReader ePub

Purpose
Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in TP53. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS.
Materials and Methods
Patients who underwent genetic counseling and confirmed with germline TP53 mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected.
Results
Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively.
Conclusion
This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required.

Citations

Citations to this article as recorded by

Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Ozgur Mete, Andrée Boucher, Kasmintan A. Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat
Endocrine Pathology.2024; 35(4): 293. CrossRef

3,396 View
196 Download
1 Crossref

Breast cancer

Androgen Receptor as a Predictive Marker for Pathologic Complete Response in Hormone Receptor–Positive and HER-2–Negative Breast Cancer with Neoadjuvant Chemotherapy: Eun-Gyeong Lee, Dong-Eun Lee, Hyun hee Kim, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Heejung Chae, Sung Hoon Sim, Keun Seok Lee, Youngmee Kwon, So-Youn Jung; Cancer Res Treat. 2023;55(2):542-550. Published online September 8, 2022; DOI: https://doi.org/10.4143/crt.2022.834

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study investigated pathological complete response (pCR) according to androgen receptor (AR) in breast cancer patients undergoing neoadjuvant chemotherapy and estimated the relationship between AR expression and clinicopathological factors.
Materials and Methods
We identified 624 breast cancer patients who underwent surgery after neoadjuvant chemotherapy at the National Cancer Center in Goyang, Korea from April 2016 to October 2019. We retrospectively collected the clinicopathologic information and AR expression results and analyzed the data according to cancer stage, hormonal receptor (HR) status, human epidermal growth factor receptor 2 (HER2) status, tumor subtype, and pCR.
Results
Among the 624 breast cancer patients, 529 (84.8%) were AR-positive (AR+) patients and 95 (15.2%) were AR-negative (AR–) patients. AR+ patients showed more estrogen receptor (ER) positivity, progesterone receptor (PR) positivity, HER2-positivity, and HR-positive and HER2-negative (HR+/HER2–) subtype. The rate of pCR was 31.4% (196/624). AR– patients had a significantly higher rate of pCR than AR+ patients (AR– 43.2% vs. AR+ 29.3%, p=0.007). The tumor factors associated with pCR were early stage, histologic grade 3, ER-negative, PR-negative, AR-negative, HER2-positive, and high Ki-67 values. In univariable analysis, AR+ significantly decreased the state of pCR (odds ratio, 0.546; 95% confidence interval, 0.349 to 0.853; p=0.008). According to tumor subtype, AR– tumor showed higher pCR rate in HR+/HER2– subtype (AR– 28.6% vs. AR+ 7.3%, p=0.022).
Conclusion
AR expression is predominant in the HR+/HER2– subtype. AR– is significantly associated with the pCR rate in breast cancer patients, especially within HR+/HER2– subtype. When determining neoadjuvant chemotherapy for the HR+/HER2– subtype, AR expression can be considered as a pCR predictive marker.

Citations

Citations to this article as recorded by

Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond
Athina Stravodimou, Ioannis A. Voutsadakis
Expert Review of Anticancer Therapy.2024; 24(3-4): 117. CrossRef
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
Miseon Lee, Tae-Kyung Yoo, Byung Joo Chae, Ahwon Lee, Yoon Jin Cha, Jieun Lee, Sung Gwe Ahn, Jun Kang
Scientific Reports.2024;[Epub] CrossRef
Evaluating the Clinico-Pathological Relationship Between Stromal Tumor-Infiltrating Lymphocytes and Androgen Receptor Expression Across Molecular Subtypes of Invasive Breast Carcinoma
Adil Aziz Khan, Sana Ahuja, Kiruthikasri G., Sufian Zaheer
Indian Journal of Surgical Oncology.2024; 15(4): 802. CrossRef
Biomarkers and translational research approaches in breast cancer—an update
Angelika M. Starzer, Anna S. Berghoff, Rupert Bartsch
memo - Magazine of European Medical Oncology.2023; 16(1): 42. CrossRef
Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Zhendong Shi, Yingxue Liu, Shichao Zhang, Shuanglong Cai, Xu Liu, Jie Meng, Jin Zhang
Discover Oncology.2023;[Epub] CrossRef

5,111 View
175 Download
5 Web of Science
5 Crossref

Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry: Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee; Cancer Res Treat. 2020;52(3):739-746. Published online February 13, 2020; DOI: https://doi.org/10.4143/crt.2019.639

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to determine the incidence of male breast cancer (MBC) and its survival outcomes in Korea, and to compare these results to those for female breast cancer (FBC).
Materials and Methods
We searched the Korea Central Cancer Registry and identified 227,122 breast cancer cases that were diagnosed between 1999 and 2016. Demographic and clinical characteristics and overall survival (OS) rates were estimated according to sex, age, histological type, and cancer stage.
Results
The 227,122 patients included 1,094 MBC cases and 226,028 FBC cases. Based on the age-standardized rate, the male: female ratio was 0.0055:1. The most common ages at diagnosis were 60-69 years for MBC and 40-49 years for FBC (p < 0.001). Male patients were less likely than female patients to receive adjuvant radiotherapy (7.5% vs. 21.8%, p < 0.001) or adjuvant chemotherapy (40.1% vs. 55.4%, p < 0.001). The 5-year OS rates after diagnosis were 88.8% for all patients, although it was significantly lower for MBC than for FBC (76.2% vs. 88.9%, p < 0.001). In both groups, older age (≥ 60 years) was associated with shorter survival. The 5-year OS rates for the invasive histological types were 75.8% for men and 89.0% for women. The 5-year OS rates in both groups decreased with increasing cancer stage.
Conclusion
MBC was diagnosed at older ages than FBC, and male patients were less likely to receive radiotherapy and chemotherapy. The survival outcomes were worse for MBC than for FBC, with even poorer outcomes related to older age, the inflammatory histological types, and advanced stage. It is important that clinicians recognize the differences between FBC and MBC when treating these patients.

Citations

Citations to this article as recorded by

Trends and Age-Period-Cohort Effect on Incidence of Male Breast Cancer from 1980 to 2019 in Taiwan and the USA
Jhao-Yang Peng, Yu-Kwang Lee, Rong-Qi Pham, Xiao-Han Shen, I-Hui Chen, Yong-Chen Chen, Hung-Shu Fan
Cancers.2024; 16(2): 444. CrossRef
The features of male breast cancer in China: A real-world study
Yuxuan Gao, Mengmeng Zhang, Gang Sun, Li Ma, Jianyun Nie, Zhongyu Yuan, Zhenzhen Liu, Yali Cao, Jianbin Li, Qiang Liu, Songqing Ye, Bo Chen, Yuhua Song, Kun Wang, Yu Ren, Guolin Ye, Ling Xu, Shu Liu, Qianjun Chen, Weiwen Li, Xinxin Chen, Peifen Fu, Wei We
The Breast.2024; 76: 103762. CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer
Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang
American Journal of Men's Health.2024;[Epub] CrossRef
Stage and Type of Male Breast Cancer Presented at Mankweng Academic Hospital from 2015-2023
Fumani Charles Makhandule, Mirza Mohamod Zahir Uddin Bhuiyan
European Journal of Medical and Health Sciences.2024; 6(6): 1. CrossRef
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S
Cancer Research and Treatment.2023; 55(1): 123. CrossRef
Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study
Ye-Seul Lee, Yu-Cheol Lim, Jiyoon Yeo, Song-Yi Kim, Yoon Jae Lee, In-Hyuk Ha
Healthcare.2023; 11(13): 1833. CrossRef
Diagnostic performance of screening mammography according to menstrual cycle among Asian women
Mi-ri Kwon, Yoosoo Chang, Inyoung Youn, Shin Ho Kook, Yoosun Cho, Boyoung Park, Seungho Ryu
Breast Cancer Research and Treatment.2023; 202(2): 357. CrossRef
Clinicopathological features and correlation analysis of male breast cancer
Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong
Medicine.2023; 102(30): e34408. CrossRef
Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
Yunuo Zhang, Heming Wu, Zhikang Yu, Liang Li, Jinhong Zhang, Xinhong Liang, Qingyan Huang
BMC Cancer.2022;[Epub] CrossRef
Poor prognosis of male triple-positive breast Cancer patients: a propensity score matched SEER analysis and molecular portraits
Biyuan Wang, Hui Wang, Andi Zhao, Mi Zhang, Jin Yang
BMC Cancer.2021;[Epub] CrossRef
Prognostic difficulties of men with breast cancer
Ian S. Fentiman
The Breast Journal.2021; 27(12): 877. CrossRef
Clinicopathological features and prognosis of male breast cancer
Xinli Wang, Shusong Liu, Yan Xue
Journal of International Medical Research.2021;[Epub] CrossRef
Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group
Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee
Journal of Breast Cancer.2021; 24(6): 561. CrossRef
Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival
Jing Zhao, Bin Wang, Jing Zhao, Yiran Mao, Jun Liu, Yanfang Yang
Thoracic Cancer.2020; 11(11): 3107. CrossRef

7,691 View
205 Download
15 Web of Science
14 Crossref

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: Eun-Gyeong Lee, Hyok Jo Kang, Myong Cheol Lim, Boyoung Park, Soo Jin Park, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Sang-Yoon Park, Boram Park, Jungnam Joo, Jai Hong Han, Sun-Young Kong, Eun Sook Lee; Cancer Res Treat. 2019;51(1):280-288. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.079

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers.
Materials and Methods
The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management.
Results
Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001).
Conclusion
RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.

Citations

Citations to this article as recorded by

A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia
Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li
Cancers.2025; 17(2): 168. CrossRef
Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO
Akiko Abe, Hidetaka Nomura, Atsushi Fusegi, Mayu Yunokawa, Arisa Ueki, Eri Habano, Hiromi Arakawa, Keika Kaneko, Yuko Minoura, Hitoshi Inari, Takayuki Ueno, Hiroyuki Kanao
Journal of Medical Genetics.2024; 61(4): 392. CrossRef
BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study
Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio
Gynecologic and Obstetric Investigation.2024; 89(2): 87. CrossRef
Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study
Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung
Cancer Research and Treatment.2024; 56(3): 802. CrossRef
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
Current Oncology.2024; 31(11): 6767. CrossRef
Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant
Yoon-Jung Choi, Younju Park, Boyoung Park, Heejung Chae, So-Youn Jung, Kum Hei Ryu, Myong Cheol Lim, Soo Jin Park, Yoon Jung Chang, Sun-Young Kong
Scientific Reports.2024;[Epub] CrossRef
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
Hidetaka Nomura, Akiko Abe, Atsushi Fusegi, Teruyuki Yoshimitsu, Satoki Misaka, Atsushi Murakami, Tsuyoshi Matsumoto, Shiho Tsumura, Motoko Kanno, Yoichi Aoki, Sachiho Netsu, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Kohei Omatsu, Mayu Yunokawa, Hiro
Scientific Reports.2023;[Epub] CrossRef
Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
Eun-Gyeong Lee, Jiwon Lim, Hyeong In Ha, Myong Cheol Lim, Yoon Jung Chang, Young-Joo Won, So-Youn Jung
Frontiers in Oncology.2023;[Epub] CrossRef
Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey
Yoon Jung Chang, Seungyeon Cho, Jungnam Joo, Kum Hei Ryu, Sangwon Lee, Juhee Cho, Myong Cheol Lim, So-Youn Jung, Jai Hong Han, Eun Sook Lee, Sun-Young Kong
Journal of Personalized Medicine.2022; 12(5): 818. CrossRef
Management of patients with BRCA mutation from the point of view of a breast surgeon
M.L. Riis
Annals of Medicine and Surgery.2021; 65: 102311. CrossRef
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Young Min Hur, Jaehee Mun, Mi-Kyung Kim, Maria Lee, Yun Hwan Kim, Seung-Cheol Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature)
D. I. Vodolazhsky, A. V. Mayakovskaya, A. V. Kubyshkin, K. A. Aliev, I. I. Fomochkina
Russian Clinical Laboratory Diagnostics.2021; 66(12): 760. CrossRef
Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
Sung Mi Jung, Jai Min Ryu, Hyung Seok Park, Ji Soo Park, Eunyoung Kang, Seeyoun Lee, Han-Byoel Lee, Hyun Jo Youn, Tae-Kyung Yoo, Jisun Kim, Jeong Eon Lee, Sang Ah Han, Dongwon Kim, Sung-Won Kim
Journal of Breast Cancer.2020; 23(6): 647. CrossRef

10,719 View
227 Download
14 Web of Science
13 Crossref

Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study: Haeyoung Kim, Won Park, Jeong Il Yu, Doo Ho Choi, Seung Jae Huh, Yeon-Joo Kim, Eun Sook Lee, Keun Seok Lee, Han-Sung Kang, In Hae Park, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2017;49(4):970-980. Published online January 4, 2017; DOI: https://doi.org/10.4143/crt.2016.382

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study was conducted to evaluate the impact of supraclavicular lymph node radiotherapy (SCNRT) on N1 breast cancer patients receiving post-lumpectomy whole-breast irradiation (WBI) and anthracycline plus taxane-based (AT) chemotherapy.
Materials and Methods
We performed a case-control analysis to compare the outcomes of WBI and WBI plus SCNRT (WBI+SCNRT). Among 1,147 patients with N1 breast cancer who received post-lumpectomy radiotherapy and AT-based chemotherapy in 12 hospitals, 542 were selected after propensity score matching. Patterns of failure, disease-free survival (DFS), distant metastasis-free survival (DMFS), and treatment-related toxicity were compared between groups.
Results
A total of 41 patients (7.6%) were found to have recurrence. Supraclavicular lymph node (SCN) failure was detected in three patients, two in WBI and one in WBI+SCNRT. All SCN failures were found simultaneously with distant metastasis. There was no significant difference in patterns of failure or survival between groups. The 5-year DFS and DMFS for patients with WBI and WBI+SCNRT were 94.4% versus 92.6% (p=0.50) and 95.1% versus 94.5% (p=0.99), respectively. The rates of lymphedema and radiation pneumonitis were significantly higher in the WBI+SCNRT than in the WBI.
Conclusion
We did not find a benefit of SCNRT for N1 breast cancer patients receiving AT-based chemotherapy.

Citations

Citations to this article as recorded by

Patient-Reported Outcomes Between Whole-Breast Plus Regional Irradiation and Whole-Breast Irradiation Only in pN1 Breast Cancer After Breast-Conserving Surgery and Taxane-Based Chemotherapy: A Randomized Phase 3 Clinical Trial (KROG 17-01)
Nalee Kim, Won Park, Haeyoung Kim, Won Kyung Cho, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Kyung Hwan Shin, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Yong Bae Kim
International Journal of Radiation Oncology*Biology*Physics.2024;[Epub] CrossRef
The optimal regional irradiation volume for breast cancer patients: A comprehensive systematic review and network meta-analysis of published studies
Wei-Xiang Qi, Lu Cao, Cheng Xu, Gang Cai, Jiayi Chen
Frontiers in Oncology.2023;[Epub] CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
What Is High-risk Breast Cancer With Pathologically Negative Lymph Nodes for Regional Recurrence?
Sang-Won Kim, Won Kyung Cho, Doo Ho Choi, Haeyoung Kim, Oyeon Cho, Won Park, Mison Chun
International Journal of Radiation Oncology*Biology*Physics.2021; 111(4): 992. CrossRef
Regional nodal irradiation in pT1-2N1 breast cancer patients treated with breast-conserving surgery and whole breast irradiation
Shin-Hyung Park, Jae-Chul Kim
Radiation Oncology Journal.2020; 38(1): 44. CrossRef
Prediction of nodal staging in breast cancer patients with 1-2 sentinel nodes in the Z0011 era
Fabio Corsi, Luca Sorrentino, Sara Albasini, Daniela Bossi, Carlo Morasso, Laura Villani, Marta Truffi
Medicine.2020; 99(35): e21721. CrossRef
Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy
Xuran Zhao, Yu Tang, Shulian Wang, Yong Yang, Hui Fang, Jianyang Wang, Hao Jing, Jianghu Zhang, Guangyi Sun, Siye Chen, Jing Jin, Yongwen Song, Yueping Liu, Bo Chen, Shunan Qi, Ning Li, Yuan Tang, Ningning Lu, Hua Ren, Yexiong Li
Radiation Oncology.2020;[Epub] CrossRef
Comparison of Dose Distribution in Regional Lymph Nodes in Whole-Breast Radiotherapy vs. Whole-Breast Plus Regional Lymph Node Irradiation: An In Silico Planning Study in Participating Institutions of the Phase III Randomized Trial (KROG 1701)
Haeyoung Kim, Heejung Kim, Won Park, Jong Yun Baek, Sung Ja Ahn, Mi Young Kim, Shin-Hyung Park, Ik Jae Lee, Inbong Ha, Jin Hee Kim, Tae Hyun Kim, Kyu Chan Lee, Hyung-Sik Lee, Tae Gyu Kim, Jin Ho Kim, Jong Hoon Lee, Jinhong Jung, Oyeon Cho, Jee Suk Chang,
Cancers.2020; 12(11): 3261. CrossRef
Clinical Significance of Lymph-Node Ratio in Determining Supraclavicular Lymph-Node Radiation Therapy in pN1 Breast Cancer Patients Who Received Breast-Conserving Treatment (KROG 14-18): A Multicenter Study
Jaeho Kim, Won Park, Jin Kim, Doo Choi, Yeon-Joo Kim, Eun Lee, Kyung Shin, Jin Kim, Kyubo Kim, Yong Kim, Sung-Ja Ahn, Jong Lee, Mison Chun, Hyung-Sik Lee, Jung Kim, Jihye Cha
Cancers.2019; 11(5): 680. CrossRef
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Research and Treatment.2018; 50(4): 1316. CrossRef

10,443 View
319 Download
9 Web of Science
10 Crossref

Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer: Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho; Cancer Res Treat. 2016;48(4):1330-1337. Published online February 3, 2016; DOI: https://doi.org/10.4143/crt.2015.463

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to identify risk factors for transient lymphedema (TLE) and persistent lymphedema (PLE) following treatment for breast cancer. Materials and Methods A total of 1,073 patients who underwent curative breast surgery were analyzed. TLE was defined as one episode of arm swelling that had resolved spontaneously by the next followup; arm swelling that persisted over two consecutive examinations was considered PLE.
Results
At a median follow-up period of 5.1 years, 370 cases of lymphedema were reported, including 120 TLE (11.2%) and 250 PLE (23.3%). Initial grade 1 swelling was observed in 351 patients, of which 120 were limited to TLE (34%), while the other 231 progressed to PLE (66%). All initial swelling observed in TLE patients was classified as grade 1. In multivariate analysis, chemotherapy with taxane and supraclavicular radiation therapy (SCRT) were associated with development of TLE, whereas SCRT, stage III cancer and chemotherapy with taxane were identified as risk factors for PLE (p < 0.05). The estimated incidence of TLE among initial grade 1 patients was calculated using up to three treatment-related risk factors (number of dissected axillary lymph nodes, SCRT, and taxane chemotherapy). The approximate ratios of TLE and PLE based on the number of risk factors were 7:1 (no factor), 1:1 (one factor), 1:2 (two factors), and 1:3 (three factors). Conclusion One-third of initial swelling events were transient, whereas the other two-thirds of patients experienced PLE. Estimation of TLE and PLE based on known treatment factors could facilitate prediction of this life-long complication.

Citations

Citations to this article as recorded by

Efficacy of preoperative lymphoscintigraphy in predicting surgical outcomes of lymphaticovenous anastomosis in lower extremity lymphedema: Clinical correlations in gynecological cancer-related lymphedema
Min Young Yoo, Kyong-Je Woo, Seo Young Kang, Byung Seok Moon, Bom Sahn Kim, Hai-Jeon Yoon, Andrea Giannini
PLOS ONE.2024; 19(1): e0296466. CrossRef
Lymphatic remapping by long-term lymphoscintigraphy follow-up in secondary lymphedema after breast cancer surgery
Garam Hong, Koeun Lee, Sangwon Han, Jae Yong Jeon
Scientific Reports.2024;[Epub] CrossRef
The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10
Shogo Nakamoto, Takayuki Iwamoto, Naruto Taira, Yukiko Kajiwara, Kengo Kawada, Daisuke Takabatake, Yuichiro Miyoshi, Shinichiro Kubo, Yoko Suzuki, Mari Yamamoto, Yutaka Ogasawara, Minami Hatono, Seiji Yoshitomi, Kyoko Hara, Asako Sasahara, Shozo Ohsumi, M
Breast Cancer.2024; 31(5): 969. CrossRef
Taxanes and Breast Cancer‐Related Lymphedema
Daniel Najafali, Charalampos Siotos, George Kokosis
Journal of Surgical Oncology.2024;[Epub] CrossRef
A Single Institution Experience With Immediate Lymphatic Reconstruction: Impact of Insurance Coverage on Risk Reduction
Anne Huang, Emma Koesters, Rebecca M. Garza, Summer E. Hanson, David W. Chang
Journal of Surgical Oncology.2024;[Epub] CrossRef
The prevalence of arm lymphedema after radiation treatment in patients with breast cancer
Kamonrat Sueangamiam, Kanisa Rongsriyam
Journal of Radiotherapy in Practice.2023;[Epub] CrossRef
The Use of Ultrasound Imaging for Upper Extremity Lymphedema after Breast Cancer: A Systematic Review
Elena Canales-Lachén, Ángel Asunsolo, Oscar J. Manrique, Javier Blázquez, Purificación Holguín, Andrés A. Maldonado
Journal of Reconstructive Microsurgery.2023; 39(02): 102. CrossRef
Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
Supportive Care in Cancer.2023;[Epub] CrossRef
Risk factors for the development of severe breast cancer-related lymphedema: a retrospective cohort study
Xiaozhen Liu, Kewang Sun, Hongjian Yang, Lingli Xia, Kefeng Lu, Xuli Meng, Yongfeng Li
BMC Cancer.2023;[Epub] CrossRef
Practical Approach to Establishing a Lymphedema Screening Program: Tips and Tricks
Derly C. Munoz, Sarah S. Virk, Oluwadamilola T. Oladeru, Pamela Clevenger, Tracy L. Hollen, Mariam W. Hanna, Lisa R. P. Spiguel
Current Breast Cancer Reports.2023; 15(3): 242. CrossRef
The impact of rehabilitation sport on breast cancer-related lymphoedema and quality of life
Bettina Boeer, Anna Seller, Birgitt Schoenfisch, Ute krainick-Strobel, Andreas Dietrich, Sara Y. Brucker, Diethelm Wallwiener, Andreas Niess, Markus Hahn
Archives of Gynecology and Obstetrics.2022; 307(5): 1529. CrossRef
The potential of gas plasma technology for targeting breast cancer
Sander Bekeschus, Fariba Saadati, Steffen Emmert
Clinical and Translational Medicine.2022;[Epub] CrossRef
Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
Frontiers in Oncology.2022;[Epub] CrossRef
Invited Commentary from the Authors of: Kuruvilla AS, et al. Risk Factors Associated With Postmastectomy Breast Cancer Lymphedema: Amulticenter Retrospective Analysis
Annet S. Kuruvilla
Annals of Plastic Surgery.2022; 89(6): 716. CrossRef
Development and validation of a nomogram to predict the risk of breast cancer-related lymphedema among Chinese breast cancer survivors
Yan-fei Liu, Jun-E Liu, Yi Zhu, Yim Wah Mak, Hui Qiu, Li-hui Liu, Shen-shen Yang, Shao-hua Chen
Supportive Care in Cancer.2021; 29(9): 5435. CrossRef
Eliminating the Burden of Lymphedema in Cancer Patients Requiring Nodal Dissections Using Prophylactic Immediate Lymphatic Reconstruction – A Case Report and Review of the Literature
Abiye Mussie, Maria C. Medor, Sylia Mohand-Said, Andrea M. Ibrahim, Carolyn Nessim, Moein Momtazi
Plastic Surgery Case Studies.2021;[Epub] CrossRef
Factors predicting one or two sentinel lymph nodes to be accepted for sentinel lymph node biopsy alone after neoadjuvant therapy in initially node-positive breast cancer patients
Li-Wei Tsai, Yi-Hsuan Lee, Chiao Lo, Huang-Chun Lien, Ming-Yang Wang, I-Shiow Jan, Ruoh-Fang Yen, Fu-Chang Hu, Chiun-Sheng Huang
Surgical Oncology.2021; 39: 101667. CrossRef
Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review
Idam de Oliveira-Junior, Eliana Aguiar Petri Nahas, Ana Cristina Cherem, Jorge Nahas-Neto, René Aloisio da Costa Vieira
Breast Care.2021; 16(1): 27. CrossRef
Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
Breast Cancer.2020; 27(1): 77. CrossRef
Lymphedema Signs, Symptoms, and Diagnosis in Women Who Are in Minority and Low-Income Groups and Have Survived Breast Cancer
Ann Marie Flores, Jason Nelson, Lee Sowles, Rebecca G Stephenson, Kathryn Robinson, Andrea Cheville, Antoinette P Sander, William J Blot
Physical Therapy.2020; 100(3): 487. CrossRef
Prevalence of obstructive sleep apnea syndrome in patients with lymphedema referred for complete decongestive therapy
Côme Roux, Béatrice Villemur, Brigitte Giovannoni, Lucie Koeyemelk, Monique Mendelson, Meriem Benmerad, Marie Joyeux-Faure, Renaud Tamisier, Jean-Louis Pepin
Journal of Vascular Surgery: Venous and Lymphatic Disorders.2020; 8(1): 137. CrossRef
The results of the intensive phase of complete decongestive therapy and the determination of predictive factors for response to treatment in patients with breast cancer related‐lymphedema
Dilek Keskin, Meltem Dalyan, Sibel Ünsal‐Delialioğlu, Ülkü Düzlü‐Öztürk
Cancer Reports.2020;[Epub] CrossRef
A scoring system for predicting the risk of breast cancer-related lymphedema
Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
International Journal of Nursing Sciences.2020; 7(1): 21. CrossRef
Lymphedema and Lymphovenous Bypass: Perioperative Nursing Implications
Lori A. Whitnell
AORN Journal.2020; 111(2): 187. CrossRef
Who Will Continuously Depend on Compression to Control Persistent or Progressive Breast Cancer-Related Lymphedema Despite 2 Years of Conservative Care?
Chul Jung, JaYoung Kim, Yu Jin Seo, Kyeong Joo Song, Ma. Nessa Gelvosa, Jin Geun Kwon, Changsik John Pak, Hyunsuk Peter Suh, Joon Pio Hong, Hwa Jung Kim, Jae Yong Jeon
Journal of Clinical Medicine.2020; 9(11): 3640. CrossRef
Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis
Alok Mohan, Bharat Jindal, Rajender Kumar Thakral, Vaseem Ansari, Veena K Sharma
Indian Journal of Pathology and Oncology.2020; 7(3): 378. CrossRef
Risk factors and prediction model for persistent breast-cancer-related lymphedema: a 5-year cohort study
I-Wen Penn, Yue-Cune Chang, Eric Chuang, Chi-Ming Chen, Chi-Feng Chung, Chia-Yu Kuo, Tien-Yow Chuang
Supportive Care in Cancer.2019; 27(3): 991. CrossRef
Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial
Gunn Ammitzbøll, Christoffer Johansen, Charlotte Lanng, Elisabeth Wreford Andersen, Niels Kroman, Bo Zerahn, Ole Hyldegaard, Merete Celano Wittenkamp, Susanne Oksbjerg Dalton
Cancer.2019; 125(10): 1683. CrossRef
Frequency and risk factors for arm lymphedema after multimodal breast-conserving treatment of nodal positive breast Cancer – a long-term observation
Julia Rupp, Catarina Hadamitzky, Christoph Henkenberens, Hans Christiansen, Diana Steinmann, Frank Bruns
Radiation Oncology.2019;[Epub] CrossRef
Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad
PLOS ONE.2019; 14(6): e0218030. CrossRef
Introduction of the Lymphedema Action Plan (LeAP): Clinical Advancement in Proactive Lymphedema Care
Renata Beaman
Rehabilitation Oncology.2019; 37(3): 122. CrossRef
Profile of women with lymphedema after breast cancer treatment
Thais de Oliveira Gozzo, Gabriela Aguado, Aniele Tomadon, Marislei Sanches Panobianco, Maria Antonieta Spinoso Prado
Escola Anna Nery.2019;[Epub] CrossRef
Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Prevention of Breast Cancer-Related Lymphedema—a Preliminary Report
Juhi Agrawal, Sandeep Mehta, Ashish Goel, Pankaj Kumar Pande, Kapil Kumar
Indian Journal of Surgical Oncology.2018; 9(3): 369. CrossRef
Progressive strength training to prevent LYmphoedema in the first year after breast CAncer – the LYCA feasibility study
Gunn Ammitzbøll, Charlotte Lanng, Niels Kroman, Bo Zerahn, Ole Hyldegaard, Klaus Kaae Andersen, Christoffer Johansen, Susanne Oksbjerg Dalton
Acta Oncologica.2017; 56(2): 360. CrossRef
Association between adjuvant docetaxel-based chemotherapy and breast cancer-related lymphedema
Wen Zhu, Dan Li, Xiaoqin Li, Jin Ren, Wenqi Chen, Hangang Gu, Yongqian Shu, Deqiang Wang
Anti-Cancer Drugs.2017; 28(3): 350. CrossRef
P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
Yunbao Pan, Yufen Yuan, Guoshi Liu, Yongchang Wei, William B. Coleman
PLOS ONE.2017; 12(2): e0172324. CrossRef
Considerations for Clinicians in the Diagnosis, Prevention, and Treatment of Breast Cancer-Related Lymphedema: Recommendations from a Multidisciplinary Expert ASBrS Panel
Sarah A. McLaughlin, Alicia C. Staley, Frank Vicini, Paul Thiruchelvam, Nancy A. Hutchison, Jane Mendez, Fiona MacNeill, Stanley G. Rockson, Sarah M. DeSnyder, Suzanne Klimberg, Michael Alatriste, Francesco Boccardo, Mark L. Smith, Sheldon M. Feldman
Annals of Surgical Oncology.2017; 24(10): 2818. CrossRef
Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245. CrossRef
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
Janine T. Hidding, Carien H. G. Beurskens, Philip J. van der Wees, Wilmy C. A. M. Bos, Maria W. G. Nijhuis-van der Sanden, Hanneke W. M. van Laarhoven
Supportive Care in Cancer.2017;[Epub] CrossRef
Palliative surgery for giant mucinous carcinoma of the breast in an elderly patient: A rare case report
Haruko Takuwa, Wakako Tsuji, Fumiaki Yotsumoto
Molecular and Clinical Oncology.2017; 7(4): 609. CrossRef
Update December 2016
Francine Blei
Lymphatic Research and Biology.2016; 14(4): 240. CrossRef

12,657 View
246 Download
45 Web of Science
41 Crossref

Effect of Time Interval between Breast-Conserving Surgery and Radiation Therapy on Outcomes of Node-Positive Breast Cancer Patients Treated with Adjuvant Doxorubicin/Cyclophosphamide Followed by Taxane: Hyeon Kang Koh, Kyung Hwan Shin, Kyubo Kim, Eun Sook Lee, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Seok Won Kim, Han-Sung Kang, Eui Kyu Chie, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee, Seock-Ah Im, Sung Whan Ha; Cancer Res Treat. 2016;48(2):483-490. Published online June 5, 2015; DOI: https://doi.org/10.4143/crt.2015.111

Abstract PDF PubReader ePub

Purpose
This study evaluated the effect of surgery-radiotherapy interval (SRI) on outcomes in patients treated with adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) and adjuvant four cycles of doxorubicin/cyclophosphamide (AC) followed by four cycles of taxane. Materials and Methods From 1999 to 2007, 397 eligible patients were diagnosed. The effect of SRI on outcomes was analyzed using a Cox proportional hazards model, and a maximal chi-square method was used to identify optimal cut-off value of SRI for each outcome.
Results
The median SRI was 6.7 months (range, 5.6 to 10.3 months). A SRI of 7 months was the significant cut-off value for distant metastasis-free survival (DMFS) and disease-free survival (DFS) using a maximal chi-square method. For overall survival, a significant cut-off value was not found. The patients with SRI > 7 months had worse 6-year DMFS and DFS than those with SRI ≤ 7 months on univariate analysis (DMFS, 81% vs. 91%, p=0.003; DFS, 78% vs. 89%, p=0.002). On multivariate analysis, SRI > 7 months did not affect DMFS and DFS. Conclusion RT delayed for more than 7 months after BCS and adjuvant four cycles of AC followed by four cycles of taxane did not compromise clinical outcomes.

Citations

Citations to this article as recorded by

MiR-210 regulates lung adenocarcinoma by targeting HIF-1α
Guolei Cao, Peiwen Fan, Ronghui Ma, Qinghe Wang, Lili He, Haiwen Niu, Qin Luo
Heliyon.2023; 9(5): e16079. CrossRef
Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
European Journal of Cancer.2022; 174: 153. CrossRef
Timing of Postmastectomy Radiotherapy Following Adjuvant Chemotherapy for High-Risk Breast Cancer: A Post-Hoc Analysis of a Randomised Controlled Clinical Trial
Si-Ye Chen, Guang-Yi Sun, Yu Tang, Hao Jing, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Xu-Ran Zhao, Yu-Chun Song, Bo Chen, Shu-Nan Qi, Yuan Tang, Ning-Ning Lu, Ning Li, Hui Fang, Ye-Xiong Li, Shu-Lian Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women
Oluwole Adeyemi Babatunde, Jan M. Eberth, Tisha Felder, Robert Moran, Samantha Truman, James R. Hebert, Jiajia Zhang, Swann Arp Adams
Journal of Racial and Ethnic Health Disparities.2021; 8(1): 147. CrossRef
How Does the Interval Between Completion of Adjuvant Chemotherapy and Initiation of Radiotherapy Impact Clinical Outcomes in Operable Breast Cancer Patients?
Lu Cao, Cheng Xu, Gang Cai, Wei-Xiang Qi, Rong Cai, Shu-Bei Wang, Dan Ou, Min Li, Kun-Wei Shen, Jia-Yi Chen
Annals of Surgical Oncology.2021; 28(4): 2155. CrossRef
Saving the Breast Saves the Lives of Breast Cancer Patients
Mohammad Esmaeil Akbari, Maryam Khayamzadeh, Hamid Reza Mirzaei, Afshin Moradi, Atieh Akbari, Farid Moradian, Neda Khalili
International Journal of Surgical Oncology.2020; 2020: 1. CrossRef
Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis
Si-Ye Chen, Yu Tang, Shu-Lian Wang, Yong-Wen Song, Hui Fang, Jian-Yang Wang, Hao Jing, Jiang-Hu Zhang, Guang-Yi Sun, Xu-Ran Zhao, Jing Jin, Yue-Ping Liu, Bo Chen, Shu-Nan Qi, Ning Li, Yuan Tang, Ning-Ning Lu, Hua Ren, Zi-Hao Yu, Ye-Xiong Li
Frontiers in Oncology.2020;[Epub] CrossRef
Evaluation of tissue computed tomography number changes and dosimetric shifts after conventional whole-breast irradiation in patients undergoing breast-conserving surgery
Joo Hwan Lee, Dong Soo Lee, So Hyun Park, Young Kyu Lee, Jeong Soo Kim, Yong Seok Kim
Tumor Biology.2018; 40(8): 101042831879188. CrossRef
The influence of timing of radiation therapy following breast-conserving surgery on 10-year disease-free survival
Marissa C van Maaren, Reini W Bretveld, Jan J Jobsen, Renske K Veenstra, Catharina GM Groothuis-Oudshoorn, Hendrik Struikmans, John H Maduro, Luc JA Strobbe, Philip MP Poortmans, Sabine Siesling
British Journal of Cancer.2017; 117(2): 179. CrossRef

11,449 View
126 Download
10 Web of Science
9 Crossref

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy: Myungsoo Kim, In Hae Park, Keun Seok Lee, Jungsil Ro, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Tae Hyun Kim, Kwan Ho Cho, Kyung Hwan Shin; Cancer Res Treat. 2015;47(3):416-423. Published online November 17, 2014; DOI: https://doi.org/10.4143/crt.2014.079

Abstract PDF PubReader ePub

Purpose
The risk for lymphedema (LE) after neoadjuvant chemotherapy (NCT) in breast cancer patients has not been fully understood thus far. This study is conducted to investigate the incidence and time course of LE after NCT. Materials and Methods A total of 313 patients with clinically node-positive breast cancer who underwent NCT followed by surgery with axillary lymph node (ALN) dissection from 2004 to 2009 were retrospectively analyzed. All patients received breast and supraclavicular radiation therapy (SCRT). The determination of LE was based on both objective and subjective methods, as part of a prospective database. Results At a median follow-up of 5.6 years, 132 patients had developed LE: 88 (28%) were grade 1; 42 (13%) were grade 2; and two (1%) were grade 3. The overall 5-year cumulative incidence of LE was 42%. LE first occurred within 6 months after surgery in 62%; 1 year in 77%; 2 years in 91%; and 3 years in 96%. In a multivariate analysis, age (hazard ratio [HR], 1.66; p < 0.01) and the number of dissected ALNs (HR, 1.68; p < 0.01) were independent risk factors for LE. Patients with both of these risk factors showed a significantly higher 5-year cumulative incidence of LE compared with patients with no or one risk factor (61% and 37%, respectively; p < 0.001). The addition of adjuvant chemotherapy did not significantly correlate with LE. Conclusion LE after NCT, surgery, and SCRT developed early after treatment, and with a high incidence rate. More frequent surveillance of arm swelling may be necessary in patients after NCT, especially during the first few years of follow-up.

Citations

Citations to this article as recorded by

Impact of neoadjuvant chemotherapy on breast cancer-related lymphedema after axillary lymph node dissection: a retrospective cohort study
Miaomiao Jia, Lihui Pan, Haibo Yang, Jinnan Gao, Fan Guo
Breast Cancer Research and Treatment.2024; 204(2): 223. CrossRef
Incidence and risk factors of breast cancer-related lymphedema in Korea: A nationwide retrospective cohort study
Ha Rim Ahn, Hyeong Eun Jeong, Choyun Jeong, Sang Yull Kang, Sung Hoo Jung, Hyun Jo Youn, Jong Seung Kim
International Journal of Surgery.2024;[Epub] CrossRef
Incidence of lymphedema related to various cancers
Marie-Eve Letellier, Marize Ibrahim, Anna Towers, Geneviève Chaput
Medical Oncology.2024;[Epub] CrossRef
Age as a risk factor for breast cancer-related lymphedema: a systematic review
Gunel Guliyeva, Maria T. Huayllani, Daniel Boczar, Francisco R. Avila, Xiaona Lu, Antonio Jorge Forte
Journal of Cancer Survivorship.2023; 17(1): 246. CrossRef
Risk factors of unilateral breast cancer-related lymphedema: an updated systematic review and meta-analysis of 84 cohort studies
Aomei Shen, Qian Lu, Xin Fu, Xiaoxia Wei, Liyuan Zhang, Jingru Bian, Wanmin Qiang, Dong Pang
Supportive Care in Cancer.2023;[Epub] CrossRef
Beyond cardiomyocytes: Cellular diversity in the heart's response to exercise
Lena E. Trager, Margaret Lyons, Alexandra Kuznetsov, Cedric Sheffield, Kangsan Roh, Rebecca Freeman, James Rhee, J. Sawalla Guseh, Haobo Li, Anthony Rosenzweig
Journal of Sport and Health Science.2023; 12(4): 423. CrossRef
Managing the Morbidity
Giacomo Montagna, Andrea V. Barrio
Surgical Oncology Clinics of North America.2023; 32(4): 705. CrossRef
Risk of Lymphedema and Death after Lymph Node Dissection with Neoadjuvant and Adjuvant Treatments in Patients with Breast Cancer: An Eight-Year Nationwide Cohort Study
Ye-Seul Lee, Yu-Cheol Lim, Jiyoon Yeo, Song-Yi Kim, Yoon Jae Lee, In-Hyuk Ha
Healthcare.2023; 11(13): 1833. CrossRef
Discussion: Variable Anatomy of the Lateral Upper Arm Lymphatic Channel: An Anatomical Risk Factor for Breast Cancer–Related Lymphedema
Mengfan Wu, Shailesh Agarwal
Plastic & Reconstructive Surgery.2023; 152(2): 430. CrossRef
Breast cancer treatment‐related arm lymphoedema and morbidity: A 6‐year experience in an Australian tertiary breast centre
Yang Yang Huang, Pei Yinn Toh, Catherine Hunt, Joshua Tzi Wei Lin, Roshi Kamyab, Ananda Kallyani Ponniah
Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 109. CrossRef
Cancer Rehabilitation Fact Sheet in Korea
Jin A Yoon, Bo Young Hong
Annals of Rehabilitation Medicine.2022; 46(4): 155. CrossRef
Burden of lymphedema in long‐term breast cancer survivors by race and age
Yumeng Ren, Michael A. Kebede, Adeyemi A. Ogunleye, Marc A. Emerson, Kelly R. Evenson, Lisa A. Carey, Sandra C. Hayes, Melissa A. Troester
Cancer.2022; 128(23): 4119. CrossRef
Acquired lymphedema: Molecular contributors and future directions for developing intervention strategies
Ika Nurlaila, Kangsan Roh, Chang-Hwan Yeom, Hee Kang, Sukchan Lee
Frontiers in Pharmacology.2022;[Epub] CrossRef
Prediction of breast cancer-related lymphedema risk after postoperative radiotherapy via multivariable logistic regression analysis
Jae Sik Kim, Jin Ho Kim, Ji Hyun Chang, Do Wook Kim, Kyung Hwan Shin
Frontiers in Oncology.2022;[Epub] CrossRef
Histological features of skin and subcutaneous tissue in patients with breast cancer who have received neoadjuvant chemotherapy and their relationship to post-treatment edema
Ayako Nakagawa, Hiroshi Fujimoto, Takeshi Nagashima, Takafumi Sangai, Mamoru Takada, Takahito Masuda, Ryotaro Teranaka, Satoshi Ota, Jun Matsushima, Shinsuke Akita, Masayuki Ohtsuka
Breast Cancer.2020; 27(1): 77. CrossRef
A scoring system for predicting the risk of breast cancer-related lymphedema
Fenglian Li, Qian Lu, Sanli Jin, Quanping Zhao, Xueying Qin, Shuai Jin, Lichuan Zhang
International Journal of Nursing Sciences.2020; 7(1): 21. CrossRef
Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema
Hélène Leray, Julie Malloizel-Delaunay, Amélie Lusque, Elodie Chantalat, Léonard Bouglon, Charlotte Chollet, Benoit Chaput, Barbara Garmy-Susini, Alexandra Yannoutsos, Charlotte Vaysse
Lymphatic Research and Biology.2020; 18(6): 510. CrossRef
Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection
Jane M. Armer, Karla V. Ballman, Linda McCall, Pamela L. Ostby, Eris Zagar, Henry M. Kuerer, Kelly K. Hunt, Judy C. Boughey
JAMA Surgery.2019; 154(9): 800. CrossRef
Breast deformation during the course of radiotherapy: The need for an additional outer margin
J. Seppälä, K. Vuolukka, T. Virén, J. Heikkilä, J.T.J. Honkanen, A. Pandey, A. Al-Gburi, M. Shah, S. Sefa, T. Koivumäki
Physica Medica.2019; 65: 1. CrossRef
Current and future perspectives on the evaluation, prevention and conservative management of breast cancer related lymphoedema: A best practice guideline
Nick Gebruers, Hanne Verbelen, Tessa De Vrieze, Lore Vos, Nele Devoogdt, Lore Fias, Wiebren Tjalma
European Journal of Obstetrics & Gynecology and Reproductive Biology.2017; 216: 245. CrossRef
Incidence and risk factors of lymphedema after breast cancer treatment: 10 years of follow-up
Ana Carolina Padula Ribeiro Pereira, Rosalina Jorge Koifman, Anke Bergmann
The Breast.2017; 36: 67. CrossRef
Risk factors for lymphoedema in women with breast cancer: A large prospective cohort
S.L. Kilbreath, K.M. Refshauge, J.M. Beith, L.C. Ward, O.A. Ung, E.S. Dylke, J.R. French, J. Yee, L. Koelmeyer, K. Gaitatzis
The Breast.2016; 28: 29. CrossRef
Identification of Prognostic Risk Factors for Transient and Persistent Lymphedema after Multimodal Treatment for Breast Cancer
Myungsoo Kim, Kyung Hwan Shin, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Eun Sook Lee, Seung Hyun Chung, Yeon-Joo Kim, Tae Hyun Kim, Kwan Ho Cho
Cancer Research and Treatment.2016; 48(4): 1330. CrossRef
Local Treatment of Breast Cancer
Joanne Lester
Seminars in Oncology Nursing.2015;[Epub] CrossRef
Discrepant Trajectories of Impairment, Activity, and Participation Related to Upper-Limb Function in Patients With Breast Cancer
Eun Joo Yang, Eunyoung Kang, Sung-Won Kim, Jae-Young Lim
Archives of Physical Medicine and Rehabilitation.2015; 96(12): 2161. CrossRef

14,744 View
120 Download
27 Web of Science
25 Crossref

Case Report

A Case of Locally Advanced Breast Cancer Complicated by Pulmonary Tumor Thrombotic Microangiopathy: Hak Jin Kim, Mi Hyang Kwak, Sun-Young Kong, Moon-Woo Seong, Han-Sung Kang, Keun Seok Lee, Jungsil Ro; Cancer Res Treat. 2012;44(4):267-270. Published online December 31, 2012; DOI: https://doi.org/10.4143/crt.2012.44.4.267

Abstract PDF PubReader ePub

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, malignancy-related complication that causes marked pulmonary hypertension, right heart failure, and death. We report on a patient with locally advanced breast cancer whose course was complicated by fatal PTTM based on clinical and laboratory findings.

Citations

Citations to this article as recorded by

Pulmonary tumor thrombotic microangiopathy: a systematic review
Rohit H. Godbole, Rajan Saggar, Nader Kamangar
Pulmonary Circulation.2019; 9(2): 1. CrossRef
Microangiopathie thrombotique tumorale pulmonaire
M. Merad, A. Alibay, S. Ammari, S. Antoun, A. Bouguerba, S. Ayed, F. Vincent
Revue des Maladies Respiratoires.2017; 34(10): 1045. CrossRef
Ante-mortem diagnosis of pulmonary tumour thrombotic microangiopathy in a patient with unrecognised extramammary Paget's disease
Aya Banno, Keijiro Chiba, Hiroko Kasai, Keiichi Nagami
BMJ Case Reports.2016; : bcr2016216666. CrossRef
Pulmonary Tumor Thrombotic Microangiopathy Associated with Advanced Gastric Cancer Successfully Treated with Chemotherapy
Seung-Hyun Yoo, Kwonoh Park, Ji Yeon Hong, Ji Yeon Kim, Jang Won Park, Yong Won Park, Kyung-Hun Lee, Kyung-So Jeon
The Ewha Medical Journal.2014; 37(2): 146. CrossRef
A Case of Pulmonary Tumor Thrombotic Microangiopathy Diagnosed by Transbronchial Lung Biopsy and Treated with Chemotherapy and Long-Term Oxygen and Anticoagulation Therapies
Atsushi Kitamura, Naoki Nishimura, Torahiko Jinta, Rika Suda, Yasuhiko Yamano, Genta Ishikawa, Yutaka Tomishima, Tsuyoshi Hamaoka, Koyu Suzuki, Naohiko Chohnabayashi
Case Reports in Pulmonology.2013; 2013: 1. CrossRef

11,237 View
64 Download
5 Crossref

First
Prev
Page of 1
Next
Last

Search